JP2022542238A5 - - Google Patents
Info
- Publication number
- JP2022542238A5 JP2022542238A5 JP2022503935A JP2022503935A JP2022542238A5 JP 2022542238 A5 JP2022542238 A5 JP 2022542238A5 JP 2022503935 A JP2022503935 A JP 2022503935A JP 2022503935 A JP2022503935 A JP 2022503935A JP 2022542238 A5 JP2022542238 A5 JP 2022542238A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- solvate
- pharmaceutically acceptable
- acceptable salt
- active agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025207487A JP2026048714A (ja) | 2019-07-26 | 2025-11-28 | 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962878852P | 2019-07-26 | 2019-07-26 | |
| US62/878,852 | 2019-07-26 | ||
| US201962901739P | 2019-09-17 | 2019-09-17 | |
| US62/901,739 | 2019-09-17 | ||
| PCT/US2020/043274 WO2021021563A1 (en) | 2019-07-26 | 2020-07-23 | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207487A Division JP2026048714A (ja) | 2019-07-26 | 2025-11-28 | 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022542238A JP2022542238A (ja) | 2022-09-30 |
| JP2022542238A5 true JP2022542238A5 (cg-RX-API-DMAC7.html) | 2023-08-16 |
| JP7783802B2 JP7783802B2 (ja) | 2025-12-10 |
Family
ID=74189909
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022503935A Active JP7783802B2 (ja) | 2019-07-26 | 2020-07-23 | 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸 |
| JP2025207487A Pending JP2026048714A (ja) | 2019-07-26 | 2025-11-28 | 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025207487A Pending JP2026048714A (ja) | 2019-07-26 | 2025-11-28 | 疾患の予防または治療に有用な官能化長鎖炭化水素モノカルボン酸及びジカルボン酸 |
Country Status (14)
| Country | Link |
|---|---|
| US (8) | US11098002B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4003314B1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7783802B2 (cg-RX-API-DMAC7.html) |
| KR (2) | KR102969367B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN118903087A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2020321945B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112022000993A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3143294C (cg-RX-API-DMAC7.html) |
| ES (1) | ES2991100T3 (cg-RX-API-DMAC7.html) |
| IL (1) | IL289919B2 (cg-RX-API-DMAC7.html) |
| MX (2) | MX2022000570A (cg-RX-API-DMAC7.html) |
| TW (2) | TW202532387A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2021021563A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA202110502B (cg-RX-API-DMAC7.html) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4003314B1 (en) | 2019-07-26 | 2024-07-10 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease |
| WO2021211039A1 (en) * | 2020-04-15 | 2021-10-21 | Medivir Ab | Miv-818/lenvatinib combination therapy for liver cancer |
| WO2022159811A1 (en) * | 2021-01-25 | 2022-07-28 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease |
| AU2022209835B2 (en) * | 2021-01-25 | 2026-05-21 | Espervita Therapeutics, Inc. | Functionalized long-chain carboxylic acids, and their use for treatment of disease |
| CN116348100A (zh) * | 2021-02-26 | 2023-06-27 | 深圳艾欣达伟医药科技有限公司 | Akr1c3活化的化合物的用途 |
| CA3216896A1 (en) * | 2021-04-28 | 2022-11-03 | Ming-Tain Lai | Combination therapy by using akr1c3-activated compound with immune checkpoint inhibitor |
| CN115887435A (zh) * | 2021-09-23 | 2023-04-04 | 博骥源(上海)生物医药有限公司 | 长链类化合物及其用途 |
| CN114736191B (zh) * | 2022-04-01 | 2023-08-08 | 上海工程技术大学 | 特普替尼中间体及其制备方法和应用 |
| CN114949230B (zh) * | 2022-06-13 | 2024-12-06 | 厦门大学附属第一医院 | 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用 |
| CN115844887B (zh) * | 2022-12-28 | 2023-09-08 | 中国人民解放军空军军医大学 | Selonsertib在制备治疗癌症的药物中的用途 |
| KR102928747B1 (ko) | 2023-07-21 | 2026-02-26 | 대한민국 | 피라졸로[1,5-에이]퀴나졸린 유도체 화합물을 포함하는 인간면역결핍바이러스 억제용 조성물 |
| CN117843938B (zh) * | 2024-03-08 | 2024-05-24 | 华东理工大学 | 一种类聚烯烃的长碳链聚酯弹性体、制备方法及其应用 |
| CN120131672B (zh) * | 2025-04-28 | 2025-12-26 | 山东大学 | 乐伐替尼联合熊去氧胆酸在肝癌治疗中的应用 |
Family Cites Families (66)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US397037A (en) | 1889-01-29 | Conductor-support | ||
| US2789970A (en) | 1953-12-08 | 1957-04-23 | Eastman Kodak Co | Polycarbonates from 1, 4-bis-(beta-hydroxyethyl)-benzenes-bis |
| GB900875A (en) | 1959-11-12 | 1962-07-11 | Sierra Eng Co | Check valve |
| US3536809A (en) | 1969-02-17 | 1970-10-27 | Alza Corp | Medication method |
| US3598123A (en) | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US3916899A (en) | 1973-04-25 | 1975-11-04 | Alza Corp | Osmotic dispensing device with maximum and minimum sizes for the passageway |
| DE2410782C2 (de) | 1974-03-07 | 1982-02-18 | Dynamit Nobel Ag, 5210 Troisdorf | Phenylendiessigsäuredialkylester und Verfahren zu deren Herstellung |
| US4008719A (en) | 1976-02-02 | 1977-02-22 | Alza Corporation | Osmotic system having laminar arrangement for programming delivery of active agent |
| US4410545A (en) | 1981-02-13 | 1983-10-18 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| US4328245A (en) | 1981-02-13 | 1982-05-04 | Syntex (U.S.A.) Inc. | Carbonate diester solutions of PGE-type compounds |
| IL64542A0 (en) | 1981-12-15 | 1982-03-31 | Yissum Res Dev Co | Long-chain alpha,omega-dicarboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| US4409239A (en) | 1982-01-21 | 1983-10-11 | Syntex (U.S.A.) Inc. | Propylene glycol diester solutions of PGE-type compounds |
| DE3423166A1 (de) * | 1984-06-22 | 1986-01-02 | Epis S.A., Zug | Alpha-, omega-dicarbonsaeuren, verfahren zu ihrer herstellung und arzneimittel, die diese verbindungen enthalten |
| KR890002631B1 (ko) | 1984-10-04 | 1989-07-21 | 몬산토 캄파니 | 생물학적으로 활성인 소마토트로핀을 지속적으로 유리하는 조성물 |
| IE58110B1 (en) | 1984-10-30 | 1993-07-14 | Elan Corp Plc | Controlled release powder and process for its preparation |
| US5073543A (en) | 1988-07-21 | 1991-12-17 | G. D. Searle & Co. | Controlled release formulations of trophic factors in ganglioside-lipsome vehicle |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IT1229203B (it) | 1989-03-22 | 1991-07-25 | Bioresearch Spa | Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative. |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| US5120548A (en) | 1989-11-07 | 1992-06-09 | Merck & Co., Inc. | Swelling modulated polymeric drug delivery device |
| US5733566A (en) | 1990-05-15 | 1998-03-31 | Alkermes Controlled Therapeutics Inc. Ii | Controlled release of antiparasitic agents in animals |
| US5580578A (en) | 1992-01-27 | 1996-12-03 | Euro-Celtique, S.A. | Controlled release formulations coated with aqueous dispersions of acrylic polymers |
| TW333456B (en) | 1992-12-07 | 1998-06-11 | Takeda Pharm Ind Co Ltd | A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide. |
| US5591767A (en) | 1993-01-25 | 1997-01-07 | Pharmetrix Corporation | Liquid reservoir transdermal patch for the administration of ketorolac |
| US5387672A (en) * | 1993-03-02 | 1995-02-07 | The University Of Maryland At Baltimore | Hemoglobin intramolecularly cross-linked withlong chain divalent reagents |
| US6087324A (en) | 1993-06-24 | 2000-07-11 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| IT1270594B (it) | 1994-07-07 | 1997-05-07 | Recordati Chem Pharm | Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida |
| US5648387A (en) | 1995-03-24 | 1997-07-15 | Warner-Lambert Company | Carboxyalkylethers, formulations, and treatment of vascular diseases |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| DE69632684T2 (de) | 1995-06-27 | 2005-06-09 | Takeda Pharmaceutical Co. Ltd. | Verfahren zur herstellung von zubereitungen mit verzögerter freisetzung |
| TW448055B (en) | 1995-09-04 | 2001-08-01 | Takeda Chemical Industries Ltd | Method of production of sustained-release preparation |
| JP2909418B2 (ja) | 1995-09-18 | 1999-06-23 | 株式会社資生堂 | 薬物の遅延放出型マイクロスフイア |
| US5980945A (en) | 1996-01-16 | 1999-11-09 | Societe De Conseils De Recherches Et D'applications Scientifique S.A. | Sustained release drug formulations |
| US6264970B1 (en) | 1996-06-26 | 2001-07-24 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| US6419961B1 (en) | 1996-08-29 | 2002-07-16 | Takeda Chemical Industries, Ltd. | Sustained release microcapsules of a bioactive substance and a biodegradable polymer |
| CA2217134A1 (en) | 1996-10-09 | 1998-04-09 | Sumitomo Pharmaceuticals Co., Ltd. | Sustained release formulation |
| ES2221019T3 (es) | 1996-10-31 | 2004-12-16 | Takeda Chemical Industries, Ltd. | Preparacion de liberacion mantenida. |
| EP0946169B1 (en) | 1996-12-20 | 2003-02-26 | Takeda Chemical Industries, Ltd. | Method of producing a sustained-release preparation |
| US5891474A (en) | 1997-01-29 | 1999-04-06 | Poli Industria Chimica, S.P.A. | Time-specific controlled release dosage formulations and method of preparing same |
| US20020037876A1 (en) * | 1998-06-25 | 2002-03-28 | Yissum Research Development Company Of Hebrew University Of Jerusalem | Carboxylic acids and derivatives thereof and pharmaceutical compositions containing them |
| US6350458B1 (en) | 1998-02-10 | 2002-02-26 | Generex Pharmaceuticals Incorporated | Mixed micellar drug deliver system and method of preparation |
| US6613358B2 (en) | 1998-03-18 | 2003-09-02 | Theodore W. Randolph | Sustained-release composition including amorphous polymer |
| KR19990085365A (ko) | 1998-05-16 | 1999-12-06 | 허영섭 | 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법 |
| US6248363B1 (en) | 1999-11-23 | 2001-06-19 | Lipocine, Inc. | Solid carriers for improved delivery of active ingredients in pharmaceutical compositions |
| US6459003B1 (en) | 1999-04-01 | 2002-10-01 | Esperion Therapeutics, Inc. | Ether compounds |
| CA2420535A1 (en) | 2000-08-30 | 2002-03-07 | Mary Tanya Am Ende | Sustained release formulations for growth hormone secretagogues |
| CN1962596A (zh) | 2000-10-11 | 2007-05-16 | 埃斯佩里安医疗公司 | 用于控制胆固醇以及相关用途的酮化合物以及组合物 |
| JP2004531459A (ja) | 2000-10-11 | 2004-10-14 | エスペリオン セラピューティクス,インコーポレイテッド | コレステロールマネージメント用スルホキシドおよびビススルホキシド化合物ならびに組成物および関連する使用 |
| CA2480415A1 (en) | 2002-04-10 | 2003-10-23 | Esperion Therapeutics, Inc. | Mimics of acyl coenzyme-a, compositions thereof, and methods of cholesterol management and related uses |
| US7335689B2 (en) | 2003-01-23 | 2008-02-26 | Esperion Therapeutics, Inc. | Dihydroxyl compounds and compositions for cholesterol management and related uses |
| JP2009521448A (ja) | 2005-12-21 | 2009-06-04 | シェーリング コーポレイション | ヒスタミンh3アンタゴニストとして有用なフェノキシピペリジンおよびそのアナログ |
| HRP20171587T1 (hr) | 2010-10-18 | 2017-12-01 | Cerenis Therapeutics Holding Sa | Spojevi, pripravci i postupci pogodni za mobilizaciju kolesterola |
| CN105997967B (zh) | 2010-10-27 | 2019-08-23 | 普罗米蒂克医药Smt有限公司 | 用于治疗癌症的化合物和组合物 |
| CN107096032A (zh) | 2011-05-16 | 2017-08-29 | 罗马克实验室有限公司 | 在有需要的对象中刺激免疫应答的方法 |
| US9572787B2 (en) | 2011-05-19 | 2017-02-21 | Rhode Island Hospital | Inhibition of renal fibrosis |
| US20140378922A1 (en) | 2013-06-25 | 2014-12-25 | Basf Se | Fluid-absorbent article with indicator |
| EP3218349A2 (en) | 2014-11-14 | 2017-09-20 | Gemphire Therapeutics Inc. | Processes and intermediates for preparing , -dicarboxylic acid-terminated dialkane ethers |
| WO2016176330A1 (en) | 2015-04-27 | 2016-11-03 | The Trustees Of The University Of Pennsylvania | Nucleoside-modified rna for inducing an adaptive immune response |
| TWI773657B (zh) | 2015-12-18 | 2022-08-11 | 美商亞德利克斯公司 | 作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物 |
| CN105801405A (zh) | 2016-05-23 | 2016-07-27 | 天津迪尔斯化学科技有限公司 | 一种降血脂小分子化合物、中间体及各自制备方法 |
| US10004761B2 (en) | 2016-06-21 | 2018-06-26 | Mark M. Levy | Malodor neutralizing composition |
| CN110200981A (zh) | 2019-06-06 | 2019-09-06 | 中国药科大学 | 五环三萜皂苷的医药用途及其药物组合物 |
| EP4003314B1 (en) | 2019-07-26 | 2024-07-10 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease |
| AU2022209835B2 (en) | 2021-01-25 | 2026-05-21 | Espervita Therapeutics, Inc. | Functionalized long-chain carboxylic acids, and their use for treatment of disease |
| WO2022159811A1 (en) | 2021-01-25 | 2022-07-28 | Espervita Therapeutics, Inc. | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids and derivatives thereof, and their use for the prevention or treatment of disease |
-
2020
- 2020-07-23 EP EP20848591.2A patent/EP4003314B1/en active Active
- 2020-07-23 EP EP24186245.7A patent/EP4464688A1/en active Pending
- 2020-07-23 CN CN202410969586.6A patent/CN118903087A/zh active Pending
- 2020-07-23 KR KR1020227005523A patent/KR102969367B1/ko active Active
- 2020-07-23 AU AU2020321945A patent/AU2020321945B2/en active Active
- 2020-07-23 CA CA3143294A patent/CA3143294C/en active Active
- 2020-07-23 TW TW113140056A patent/TW202532387A/zh unknown
- 2020-07-23 US US16/937,154 patent/US11098002B2/en active Active
- 2020-07-23 WO PCT/US2020/043274 patent/WO2021021563A1/en not_active Ceased
- 2020-07-23 ES ES20848591T patent/ES2991100T3/es active Active
- 2020-07-23 BR BR112022000993A patent/BR112022000993A2/pt unknown
- 2020-07-23 IL IL289919A patent/IL289919B2/en unknown
- 2020-07-23 MX MX2022000570A patent/MX2022000570A/es unknown
- 2020-07-23 JP JP2022503935A patent/JP7783802B2/ja active Active
- 2020-07-23 KR KR1020267015915A patent/KR20260085169A/ko active Pending
- 2020-07-23 CN CN202080052472.5A patent/CN114126593B/zh active Active
- 2020-07-23 TW TW109124977A patent/TWI862642B/zh active
-
2021
- 2021-03-03 US US17/190,844 patent/US11084773B1/en active Active
- 2021-04-26 US US17/240,513 patent/US11267778B2/en active Active
- 2021-07-12 US US17/373,110 patent/US20220402851A1/en not_active Abandoned
- 2021-12-15 ZA ZA2021/10502A patent/ZA202110502B/en unknown
-
2022
- 2022-01-07 US US17/571,107 patent/US20230007838A1/en not_active Abandoned
- 2022-01-13 MX MX2025002978A patent/MX2025002978A/es unknown
-
2023
- 2023-06-01 US US18/204,442 patent/US12180151B2/en active Active
-
2024
- 2024-08-22 US US18/812,284 patent/US12252467B2/en active Active
-
2025
- 2025-03-07 AU AU2025201689A patent/AU2025201689A1/en active Pending
- 2025-03-17 US US19/082,112 patent/US20250367149A1/en active Pending
- 2025-11-28 JP JP2025207487A patent/JP2026048714A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101932238B (zh) | 使用半胱胺制品治疗非酒精性脂肪性肝炎(nash)的方法 | |
| TWI764943B (zh) | 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途 | |
| JP2022121594A5 (cg-RX-API-DMAC7.html) | ||
| JP2007515469A5 (cg-RX-API-DMAC7.html) | ||
| IL289919B1 (en) | Functionalized long-chain hydrocarbon mono- and di-carboxylic acids useful for the prevention or treatment of disease | |
| CA2515424A1 (en) | The combined use of cruciferous indoles and chelators for the treatment of papillomavirus-related conditions | |
| JP2020517696A5 (cg-RX-API-DMAC7.html) | ||
| JP2024502446A5 (cg-RX-API-DMAC7.html) | ||
| CN112245419A (zh) | 包括15-hepe的组合物以及使用其治疗或预防纤维化的方法 | |
| WO2017177947A1 (zh) | 局部注射双硫仑制剂治疗胸腹膜癌症的方法 | |
| He et al. | Efficacy of capecitabine and oxaliplatin regimen for extrahepatic metastasis of hepatocellular carcinoma following local treatments | |
| TWI598095B (zh) | 治療或緩解高齡或末期癌症患者用之醫藥組合物 | |
| TWI822897B (zh) | 一種抗pd-1抗體和法米替尼聯合在製備治療腫瘤的藥物中的用途 | |
| CN112870365A (zh) | Ezh2抑制剂和/或parp抑制剂与化疗药物联合在制备治疗肿瘤药物中的用途 | |
| RU2016103912A (ru) | Новый способ применения железа и новые композиции, приспособленные для указанной цели | |
| AU2006221479B2 (en) | Method of treating liver cancer | |
| TW201932120A (zh) | 用於具有異檸檬酸脫氫酶突變的腫瘤的藥物組成物與抗腫瘤劑及其應用 | |
| LoRusso et al. | Lack of food effect on single-dose pharmacokinetics of brivanib, and safety and efficacy following multiple doses in subjects with advanced or metastatic solid tumors | |
| Mondal et al. | ORAL SMALL-MOLECULE LIVER-TROPIC PD-L1 INHIBITOR PHARMACOKINETICS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA | |
| CN121695138A (zh) | 一类n-取代苯基-2-吡啶酮化合物在治疗癌症中的应用 | |
| CN112891510A (zh) | 采用iap抑制剂的治疗方法 | |
| HK40044248A (en) | Treatment method with iap inhibitor | |
| Gaglio et al. | Induction therapy using 9 mcg vs. 15 mcg of infergen daily for heptatitis C infected patients who have failed previous interferon therapy | |
| Gaglio et al. | Daily induction therapy followed by every other day dosing with Infergen® for HCV patients naive to interferon therapy | |
| Furuse et al. | Pilot study of transhepatic arterial chemoembolization with degradable starch microspheres in patients with hepatocellular carcinoma |